About
Our Company
Arrivent was founded in 2021 with a mission to identify, develop and commercialize differentiated medicines from around the world to address the unmet medical needs of patients with difficult-to-treat diseases, beginning with cancer.
Recognizing the plethora of innovative therapies initially developed in geographies such as China, Europe, South Korea and Japan—and recognizing the risk that they otherwise may not reach global populations outside of the geographies where they were developed—we have made it our mission to ensure these medicines reach patients and physicians across the globe.
This is R&D Done Differently
Since our inception, we have assembled a team of world-class life sciences professionals with proven track records of charting the most direct and expedient path to drug approval. Our team’s deep knowledge in oncology has allowed us to identify novel therapeutic programs with strong biologic and scientific rationale that we believe have the potential to offer a differentiated safety and efficacy profile to patients. Based on our extensive experience working with regulatory agencies, we design development strategies that maximize the potential of the drug candidate and have a clear path to regulatory approval. We believe our highly selective in-licensing strategy provides us with high-quality development candidates at preclinical or clinical stages, which, if approved, would have the potential to improve the lives of patients and achieve global commercial success.
Our Partners
We are therapeutic-class agnostic in our ability to identify and rapidly develop innovative medicines for patients regardless of where the drug was initially discovered. We leverage our scientific knowledge and broad experience in drug development to identify high-quality candidates with strong development potential, and work with scientific founders and their companies to bring these drugs to global populations as quickly as possible.
Our lead clinical asset firmonertinib is an example of how we are building our pipeline based on a strong understanding of cancer biology and unmet medical need in partnership with Allist, and we are applying these same skills to other medicines and research collaborations as well.
We welcome discussion on meaningful strategic collaborations: BD@arrivent.com
